Eli Lilly Sees Positive Indian Response to Mounjaro
Source: Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand (2025-06-21)
Eli Lilly has reported a positive response from India regarding its obesity drug, Mounjaro, and plans to focus on the market through 2025. The company is optimistic about expanding its presence in India, aiming to leverage the growing demand for obesity treatments and diabetes management solutions. The pharmaceutical giant highlighted that India presents significant opportunities for Mounjaro, especially as awareness and acceptance of obesity-related health issues increase. Lilly intends to tailor its strategies to the Indian market, emphasizing local needs and regulatory pathways to accelerate the drug's availability and adoption.
More recent coverage
- Iranian Militias Threaten US Amid Rising Iraq Tensions
- AFSBn-Poland Welcomes New Leadership at Modern APS Site
- GIJN Expands Global Membership with 12 New Countries
- Global Markets Surge Amid Economic Optimism
- China-Taiwan Dispute Over Historical Claims Escalates
- June Lockhart Celebrates 100 Years of Iconic Acting
- Jane Austen's Legacy Celebrated at 250th Anniversary
- Bernie Sanders Backs Key House Race in Trump’s 2024 Battleground
- Chelsea Aims to Capture America's Heart with Bold Transfer Strategy